Phase 2 Trial of Pembrolizumab and Olaparib (POLAR) Maintenance for Patients (pts) with Metastatic Pancreatic Cancer (mpdac): Two Cohorts B Non-Core Homologous Recombination Deficiency (HRD) and C Exceptional Response to Platinum-Therapy
JOURNAL OF CLINICAL ONCOLOGY(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要